Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

516 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.
Stroopinsky D, Rosenblatt J, Ito K, Mills H, Yin L, Rajabi H, Vasir B, Kufe T, Luptakova K, Arnason J, Nardella C, Levine JD, Joyce RM, Galinsky I, Reiter Y, Stone RM, Pandolfi PP, Kufe D, Avigan D. Stroopinsky D, et al. Among authors: pandolfi pp. Cancer Res. 2013 Sep 1;73(17):5569-79. doi: 10.1158/0008-5472.CAN-13-0677. Epub 2013 Jul 18. Cancer Res. 2013. PMID: 23867470 Free PMC article.
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.
Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant MP, Cole L, Palmer K, Somaiya P, Karp Leaf R, Nahas M, Apel A, Jain S, McMasters M, Mendez L, Levine J, Joyce R, Arnason J, Pandolfi PP, Kufe D, Rosenblatt J, Avigan D. Pyzer AR, et al. Among authors: pandolfi pp. Blood. 2017 Mar 30;129(13):1791-1801. doi: 10.1182/blood-2016-07-730614. Epub 2017 Jan 26. Blood. 2017. PMID: 28126925 Free PMC article.
Pro-senescence therapy for cancer treatment.
Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Nardella C, et al. Among authors: pandolfi pp. Nat Rev Cancer. 2011 Jun 24;11(7):503-11. doi: 10.1038/nrc3057. Nat Rev Cancer. 2011. PMID: 21701512 Review.
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.
Mugoni V, Panella R, Cheloni G, Chen M, Pozdnyakova O, Stroopinsky D, Guarnerio J, Monteleone E, Lee JD, Mendez L, Menon AV, Aster JC, Lane AA, Stone RM, Galinsky I, Zamora JC, Lo-Coco F, Bhasin MK, Avigan D, Longo L, Clohessy JG, Pandolfi PP. Mugoni V, et al. Among authors: pandolfi pp. Cell Res. 2019 Jun;29(6):446-459. doi: 10.1038/s41422-019-0162-7. Epub 2019 Apr 25. Cell Res. 2019. PMID: 31024166 Free PMC article.
PML targeting eradicates quiescent leukaemia-initiating cells.
Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, Pandolfi PP. Ito K, et al. Among authors: pandolfi pp. Nature. 2008 Jun 19;453(7198):1072-8. doi: 10.1038/nature07016. Epub 2008 May 11. Nature. 2008. PMID: 18469801 Free PMC article.
The APL paradigm and the "co-clinical trial" project.
Nardella C, Lunardi A, Patnaik A, Cantley LC, Pandolfi PP. Nardella C, et al. Among authors: pandolfi pp. Cancer Discov. 2011 Jul;1(2):108-16. doi: 10.1158/2159-8290.CD-11-0061. Cancer Discov. 2011. PMID: 22116793 Free PMC article. Review.
516 results